Senior/Principal Scientist

The Discovery Biology group is seeking a Senior/Principal Scientist with deep experience in biologics, focused on antibody therapeutics. The ideal candidate will also have a solid background in the construction and characterization of bispecific antibodies, especially T-cell engagers. Prior experience with program leadership is preferred. This is a critical position in the Discovery Biology group and will have the opportunity to collaborate across groups to contribute to and lead multiple fast-moving bispecific IgM projects.

Responsibilities:

  • Lead effort on new TAA X CD3 bispecific IgM project(s).
  • Contribute to target selection and due diligence of candidate tumor associated antigens.
  • Rapidly acquire expert knowledge on one or more tumor targets/therapeutic areas.
  • Collaborate with molecular biology and protein production/purification/analytics teams to generate material for in vitro and early in vivo studies.
  • Work extensively with internal and external collaborators to make and test competing bispecific molecules and keep abreast of literature and clinical trial data in field.
  • Design and execute experiments for advanced in vivo studies in collaboration with preclinical sciences team.
  • Collaborate with Process Sciences and Manufacturing team to build production cell lines.
  • Generate reports for supporting IND filing and patents as program moves from Research to Manufacturing and Development.

Qualifications:

  • Ph.D. in biological sciences or related fields with 6 + years of post-PhD experience in biopharma industry, preferably in a startup environment.
  • Prior experience with generation of and optimization of biologics for multiple therapeutic indications.
  • Demonstrated experience with all phases of preclinical research with antibody and antibody-like biologics – molecular biology, mammalian cell culture, transfection, protein production, purification, characterization using in vitro biochemical and cell biology assays.
  • Prior knowledge and experience working with bispecific antibodies and sound understanding of T-cell biology.
  • Excellent organization, interpersonal, and communication skills, ability to work in a fast-paced environment.
  • Ability to effectively mentor and develop Research Associates and lead projects in a matrix organization.
  • Demonstrated track record of publications in top-tier journals and/or patents.
  • Being a consummate team player and respectful of others is a must.
  • Able to commute to Mountain View.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 
 
Apply to this position

Research Associate, Protein Purification

We are seeking a Research Associate with a background in immunological, biochemical, and protein chemistry techniques. In this important position, you will support the Discovery Biology group primarily in protein characterization (SDS-PAGE, ELISA, western blots, Endotoxin assays, etc) and functional assays in cell-based systems (Luminescent or flow cytometry based assays).

Responsibilities:

  • Perform protein purification of small to large scale antibodies using AKTA PRIME, AKTA START and AKTA pure.
  • Measure supernatant titer by ELISA or SEC.
  • Characterize antibody by SEC, UV, Endotoxin assay, SDS-PAGE, Western Blots.
  • Prepare Data Package and CofA.
  • Perform high throughput purification using Hamilton Nimbus.
  • Stable/transient plasmid transfection of suspension/adherent mammalian cell cultures.
  • Ensure high-quality, timely documentation in electronic laboratory notebooks and technical reports.
  • Work as part of a cross-functional team.

Qualifications:

  • Bachelor’s degree (BS) in Cell Biology, Molecular Biology, Biochemistry with 2 years of  experience, preferably in a startup biotech environment.
  • Experience with protein purification and characterization assays (SDS-PAGE, ELISA, western blots, Endotoxin assays, etc).
  • Knowledge of basic computer programs routinely used in a lab such as MS Word, Powerpoint, Excel, GraphPad etc; ability to quickly learn and master new instrument software and programs.
  • Excellent organization, interpersonal, and communication skills.
  • Being a team player and respectful of others is a must.
  • Experience with mammalian cell culture and micro-titer plate based readouts for cell proliferation and/or killing.
  • Experience in maintaining thorough lab records, and adhering to health and safety regulations.
  • Able to thrive in a fast-paced, start-up environment.
  • Must be able to commute to Mountain View.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 
 
Apply to this position

Director, Antibody Pharmacology

Our Preclinical Sciences group is seeking a Director of Antibody Pharmacology.   In this critical role, you will be responsible for investigating the in vivo pharmacology aspects of drug discovery programs in a variety of disease areas, and at various stages of preclinical and/or development.  You’ll collaborate closely with both internal and external scientists.  In this position, you’ll report to the VP of Preclinical Sciences, and will actively participate in the expansion of the Preclinical team.

Requirements:

  • PhD in Pharmacology, Molecular Biology, Cell Biology or related field.
  • 7 + years of relevant industry experience in a biotech or biopharmaceutical setting.
  • Proven in vivo physiology and pharmacology skills in rodent and non-rodent animal models, and experience overseeing the design, execution and interpretation of non-clinical in vivo pharmacology studies and preparing successful IND submissions.
  • Extensive experience leading the in vivo pharmacology aspects of drug discovery and development from target validation to IND-enabling studies.
  • Demonstrated creativity and novel approaches to solving scientific problems.
  • Knowledge of preclinical and clinical biomarker discovery and development.
  • Deep understanding of preclinical PK/PD/efficacy relationships and their translation to the clinic.
  • Extensive experience with engaging and managing external in vivo efforts with contract research organizations, as well as with academic collaborators.
  • A collaborator who communicates in an open, clear, complete, timely and consistent manner.
  • Able to work in a fast-paced, start-up environment.
  • Able to commute to Mountain View.

 Responsibilities:

  • Lead the antibody pharmacology aspects of multiple product development projects, provide in vivo physiology and pharmacology expertise to successfully bringing programs to IND submission.
  • Propose, plan and manage study execution at external CROs, and data interpretation to characterize the company’s drug candidates and their in vivo mechanism of action to move programs from discovery to clinical development.
  • Investigate the pharmacokinetics, pharmacodynamics and biodistribution of IgM- and IgA-based therapeutics.
  • Plan and implement translational research including pharmacodynamic markers of target engagement, biomarkers predictive of or correlating with clinical efficacy and disease biology.
  • Contribute to preparation of study reports, regulatory filings and project presentations.
  • Interface with external partners, clinical and academic collaborators, and CROs.
  • Provide updates and advice to Preclinical, project teams and senior management, including evaluation of data and their potential impact on drug programs and clinical/regulatory strategy.
  • Keep abreast of emerging novel and translational animal models that could facilitate identification and validation of new targets or development of new therapeutics.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 
 
Apply to this position

Director of Manufacturing

Our Manufacturing and Process Sciences group is seeking a Director of Manufacturing.   In this critical role, you will be responsible providing functional leadership for supply chain strategy, logistics, warehousing/distribution, manufacturing, site safety, quality, and employee engagement.

Requirements:

  • B.S. degree in Engineering, Science or related field, and 15+ years in manufacturing biologics.
  • Minimum of 5 years of management and leadership experience.
  • Knowledge of cGMP manufacturing requirements related to clinical production and commercial manufacturing of injectable products.
  • Lean Manufacturing implementation experience.
  • Strong leader and mentor.
  • Excellent verbal and written communication.
  • Extremely well organized with great attention to detail.
  • Able to work in a fast-paced, start-up environment.
  • “Roll up the sleeves” mentality.

Responsibilities:

  • Development of manufacturing plan and establishment of procedures to ensure high standards of quality, safety, efficiency and schedule compliance.
  • Oversee the internal construction of manufacturing capability, while managing ongoing external manufacturing to meet clinical requirements.
  • Hire, train, develop and evaluate team. Hold direct reports accountable for performance.
  • Partner with Quality and Safety to ensure compliance with quality and safety best practices.
  • Drive process improvement and metric progress in key areas of responsibility: safety/culture, quality/delivery, cost-effectiveness, efficiency.
  • Head the RFP and diligence process for all external manufacturing contracts.
  • Preparation of CMC documentation for regulatory submissions.

Must be able to travel ~10% of the time.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 
 
Apply to this position

Scientist, Upstream Process Sciences

We are hiring a Scientist in our Upstream Process Sciences group to join our rapidly growing team. In this important position, you will support the development of novel antibody products by helping to create upstream processes producing these therapeutic antibodies. You will perform cell culture process development, scale-up, and technology transfer to help advance novel cancer therapies into human clinical studies.

Responsibilities:

  • Independently design, execute, and interpret cell culture experiments to answer specific scientific questions.
  • Experience with operating benchtop bioreactors, pilot scale bioreactors and mini bioreactors such as AMBR250.
  • Develop innovative technologies and enhance cell culture process understanding.
  • Scale up cell culture processes in a 200 L disposable bioreactor.
  • Collaborate closely with purification development group and other groups to meet project timelines.
  • Lead the tech transfer of cell culture processes for GMP manufacturing.
  • Participate in platform optimization efforts. Expertise with media/feed optimization and perfusion cultures is a plus.
  • Write technical development reports, GMP campaign summary reports and relevant sections in regulatory filings.
  • Publish or present scientific findings in peer-reviewed journals or conferences.

Qualifications:

  • Scientific degree in chemical engineering, bioengineering, or a related field, with at least 0 to 2 years of direct experience for PhD, or > 6 years for MS, or > 8 years for BS.
  • Proficiency using Microsoft Office.
  • Aseptic technique.
  • Able to multitask.
  • Able to thrive in a fast-paced, start-up environment.

This job involves working under BSL-2 conditions.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

 
 
Apply to this position

IGM Biosciences Announces $102 Million Series C Financing to Advance its IgM Antibody Platform and Pipeline

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of engineered IgM antibodies for therapeutic use, today announced the closing of its $102 million Series C financing. New investors included Redmile Group, Janus Henderson Investors, Vivo Capital and another large U.S.-based, healthcare-focused fund. Haldor Topsøe Holding A/S, which has funded IGM since 2010, also participated in the round.

“We are very pleased to have the support of these sophisticated healthcare-focused investors,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “We look forward to working with them to realize the potential of our IgM platform to deliver new therapeutic treatments to patients with cancer.”

Proceeds from this financing will be used to advance the Company’s IgM platform technology and its proprietary oncology pipeline, including its lead program, a CD20 x CD3 bispecific antibody, which is expected to enter the clinic later this year.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that is focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies, and IGM believes it has the most advanced research and development program focused on engineered IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent advantages may provide superior performance, as compared to IgG antibodies. For more information about IGM Biosciences, its technologies and its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbiosciences@argotpartners.com

Biomarker Scientist

IGM Biosciences is seeking an experienced Biomarker Scientist to successfully strategize, build and execute on the Development Biomarker efforts for our clinical programs.

Qualifications:

  • PhD or MD PhD.
  • Experience leading and executing on clinical cancer immunotherapy biomarker programs.
  • Strong drive to succeed.
  • Able to think strategically and work effectively in a fast-paced environment.
  • Excellent written and verbal communication.
  • Strong collaboration skills.
  • Able to thrive in a fast-paced, start-up environment.

 
IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors

Dr. Kathy Behrens brings 35 years of biotech and investment industry experience and leadership

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of M. Kathleen Behrens, Ph.D., to its Board of Directors. Dr. Behrens has been a pioneer in the biotech industry throughout her career, beginning as an equity research analyst at Robertson Stephens & Co. She has been an industry leader in a wide variety of roles, including equity research analyst, venture capital investor, public equity investor, entrepreneur, executive, director and public policy and industry trade group committee member.

Dr. Behrens currently serves as the Chair of the Board of Directors of Sarepta Therapeutics, Inc. and has been a member of its Board since 2009.

“Kathy brings a unique perspective to IGM’s Board – one that has been shaped by a successful career as an entrepreneur, company founder, private and public investor, director, public policy expert and management advisor across the life sciences industry. IGM is honored to have her join us at this exciting point in our development,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Importantly, Kathy has first-hand experience guiding an antibody platform company from its inception as a privately held entity to a successful publicly traded company with a deep pipeline. Kathy’s financial industry experience also adds a key perspective to our Board as we look to build our infrastructure and strategy for 2019 and beyond. We are very pleased that Kathy will be joining the Company, and IGM will benefit greatly from her counsel and experience.”

“IGM is looking to unlock the inherent advantages that IgM antibodies may have over currently available IgG antibody treatments. It is the ingenuity and passion of companies like IGM that has excited and engaged me in this industry for the past 35 years, and it is why I remain a steadfast believer in its ability to evolve, innovate and create new products for the treatment of life-threatening human diseases,” commented Dr. Behrens. “I look forward to working with IGM, and I am very excited by the prospect of witnessing its progress firsthand.”

Dr. Behrens played an important role in the founding of one of the seminal antibody platform companies, Protein Design Labs, Inc. She also served as a director of the groundbreaking antibody platform company, Abgenix, Inc., from the company’s early rounds of private financings through its sale to Amgen Inc. Dr. Behrens also served as a director of Amylin Pharmaceuticals, Inc. from 2009 until its sale to Bristol-Myers Squibb Company.

Dr. Behrens serves as a member of the Steering Committee of the Coalition for 21st Century Medicine, of which she was a co-founder. She has served as a member of the President’s Council of Advisors on Science and Technology (“PCAST”) and as chairwoman of PCAST’s subcommittee on Personalized Medicine. She has been a director on the Board on Science, Technology and Economic Policy of the National Research Council and has also served as a director, president and chairwoman of the National Venture Capital Association.

Dr. Behrens began her career in the financial services industry as an equity research analyst with Robertson Stephens & Co., where she became a general partner, managing director and venture capital investor. Dr. Behrens continued in her venture capital management capacity as a general partner for selected venture funds of RS Investments after a management-led buyout of the firm from Bank of America Corporation.

Dr. Behrens holds a Ph.D. in Microbiology from the University of California, Davis.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases since 2010. IGM Biosciences is working to develop IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer

Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience 

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Misbah Tahir to the newly created position of Chief Financial Officer. Mr. Tahir joins IGM with more than twenty years of experience in finance and strategic planning, including public market financings and product launches. Most recently, Mr. Tahir was Vice President, Head of Finance at Dermira, Inc., where he helped build the finance, treasury, accounting and SEC compliance and reporting functions during a period of rapid growth, and played an integral role in the company’s initial public offering and follow-on public financings.

“We are very pleased that Misbah has decided to join the IGM team, and his skills and leadership will be pivotal to the development of our financial infrastructure, capabilities and strategy at this exciting time in our growth as a company,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “His experience in building finance and accounting organizations, managing financial and strategic planning processes and interfacing with the biotechnology capital markets will be critical to IGM as we move a potentially transformative new therapeutic approach toward clinical proof of concept studies and eventual market launch.”

“IGM is pioneering an entirely new class of therapeutic drugs for the treatment of cancer and other serious diseases through its proprietary IgM antibody technology,” added Mr. Tahir. “The potential of this platform and the inspired, passionate and determined environment that defines IGM drew me to this opportunity. I am excited to become part of this experienced team that is devoted to delivering important advances in antibody-based therapies and the treatment of urgent unmet medical needs.”

During his career in the biotechnology industry, Mr. Tahir has helped finance, advance and launch multiple new therapeutic drugs. While at Dermira, Mr. Tahir was a key member of the financing team, which raised over $750 millionto advance the company’s clinical programs and corporate development, and he was a leader in Dermira’s transition to a commercial-stage company.

Prior to his role at Dermira, Mr. Tahir was Director, Head of Commercial Financial Planning and Analysis at Onyx Pharmaceuticals, Inc., where he served as finance business partner to the Chief Commercial Officer during the U.S. and international launches of Kyprolis® for multiple myeloma and was responsible for the financial planning processes across Onyx’s product portfolio supporting annual product sales in excess of $1 billion. Before that, he was Associate Director of Revenue at Human Genome Sciences, Inc. (HGS), where he led all revenue and collaboration accounting activities during the U.S. launch of Benlysta® and was Chair of the HGS-GlaxoSmithKline Joint Finance Committee.

Prior to HGS, Mr. Tahir spent six years at Amgen, Inc. in finance and accounting management roles. He began his professional career at the global management consulting firm Oliver Wyman, where he developed business development and market-entry strategies for diverse clients.

Mr. Tahir received an MBA from the University of Michigan Business School and a BA from the University of Pennsylvania.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases since 2010. IGM Biosciences is working to develop IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.